Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCC9 | O60706 | 19/20 | 0.66 |
| ▸ | ABCC8 | Q09428 | 19/20 | 0.66 |
| ▸ | KCNJ11 | Q14654 | 19/20 | 0.66 |
| ▸ | KCNJ8 | Q15842 | 19/20 | 0.66 |
| ▸ | GPR174 | Q9BXC1 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6432045 | 0.90 | ABCC9 (0.54) | ABCC9ABCC8KCNJ11KCNJ8GPR174 | |
| SCHEMBL7234165 | 0.87 | ABCC9 (0.50) | ABCC9ABCC8KCNJ11KCNJ8 | |
| SCHEMBL6432959 | 0.86 | ABCC9 (0.49) | ABCC9ABCC8KCNJ11KCNJ8 | |
| SCHEMBL6432586 | 0.86 | ABCC9 (0.61) | ABCC9ABCC8KCNJ11KCNJ8 | |
| SCHEMBL7241851 | 0.86 | ABCC9 (0.49) | ABCC9ABCC8KCNJ11KCNJ8 | |
| SCHEMBL6432167 | 0.85 | ABCC9 (0.68) | ABCC9ABCC8KCNJ11KCNJ8 | |
| SCHEMBL7621290 | 0.84 | ABCC9 (0.49) | ABCC9ABCC8KCNJ11KCNJ8 | |
| SCHEMBL6433267 | 0.83 | ABCC9 (0.63) | ABCC9ABCC8KCNJ11KCNJ8 | |
| SCHEMBL6436245 | 0.83 | ABCC9 (0.72) | ABCC9ABCC8KCNJ11KCNJ8 | |
| SCHEMBL6431808 | 0.83 | ABCC9 (0.72) | ABCC9ABCC8KCNJ11KCNJ8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1194429-B1 | POTASSIUM CHANNEL OPENERS | ABBOTT LAB (US) | 2005-03-30 | — | — | EP | claimed |
| US-6593335-B1 | Disease than can be ameliorated with a potassium channel opener in a host mammal, comprising administering to the mammal in need thereof a therapeutically effective amount of the compound of claim 1; said disease is epilepsy, Raynaud's | ABBOTT LABORATORIES | 2003-07-15 | — | — | US | claimed |
| EP-1194429-A1 | POTASSIUM CHANNEL OPENERS | Abbott Laboratories (US) | 2002-04-10 | — | — | EP | claimed |
| WO-2000078768-A1 | POTASSIUM CHANNEL OPENERS | ABBOTT LABORATORIES (US) | 2000-12-28 | — | — | WO | claimed |
| EP-1194429-B1 | POTASSIUM CHANNEL OPENERS | ABBOTT LAB (US) | 2005-03-30 | — | — | EP | disclosed |
| US-6593335-B1 | Disease than can be ameliorated with a potassium channel opener in a host mammal, comprising administering to the mammal in need thereof a therapeutically effective amount of the compound of claim 1; said disease is epilepsy, Raynaud's | ABBOTT LABORATORIES | 2003-07-15 | — | — | US | disclosed |